Cover Image
市場調查報告書

Heptares Therapeutics Ltd.的產品平台分析

Heptares Therapeutics Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251673
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Heptares Therapeutics Ltd.的產品平台分析 Heptares Therapeutics Limited - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 45 Pages
簡介

Heptares Therapeutics Ltd.是總公司設立於英國的藥物研發企業,利用獨家平台技術,致力於以G蛋白質共軛受體(GPCR)為標之低分子治療藥的藥物研發及開發。

本報告提供Heptares Therapeutics Ltd. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Heptares Therapeutics Ltd. 的基本資料

  • Heptares Therapeutics Ltd. 概要
  • 主要資訊
  • 企業資料

Heptares Therapeutics Ltd. :R&D概要

  • 主要的治療範圍

Heptares Therapeutics Ltd. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Heptares Therapeutics Ltd. :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Heptares Therapeutics Ltd. :藥物簡介

  • HTL-9936
  • Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment
  • Drug to Agonize Muscarinic M4 Receptors for Psychosis
  • HTL-14242
  • Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes
  • Small Molecule to Agonize GPR-39 for Type 2 Diabetes
  • Small Molecule to Antagonize CGRP for Migraine
  • Monoclonal Antibody to Target GPCR for Pain, Metabolic Disorders and Inflammation
  • Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia
  • Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders
  • Small Molecule to Antagonize Orexin 1/2 for Insomnia
  • Small Molecule to Target Chemokine (C-X-C Motif) Receptor 4 for Cancer and HIV
  • Small Molecule to Target GPCR for CNS Disorders
  • Small Molecule to Target mGluR2 for Schizophrenia
  • Small Molecules to Target GPCR
  • Small Molecules to Target GPCRs for Pain, Metabolic Disorders and Inflammation

Heptares Therapeutics Ltd. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Heptares Therapeutics Ltd. :最新的開發平台資訊

Heptares Therapeutics Ltd. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07960CDB

Summary

Global Markets Direct's, 'Heptares Therapeutics Limited - Product Pipeline Review - 2016', provides an overview of the Heptares Therapeutics Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Heptares Therapeutics Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Heptares Therapeutics Limited
  • The report provides overview of Heptares Therapeutics Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Heptares Therapeutics Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Heptares Therapeutics Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Heptares Therapeutics Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Heptares Therapeutics Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Heptares Therapeutics Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Heptares Therapeutics Limited Snapshot
    • Heptares Therapeutics Limited Overview
    • Key Information
    • Key Facts
  • Heptares Therapeutics Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Heptares Therapeutics Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Heptares Therapeutics Limited - Pipeline Products Glance
    • Heptares Therapeutics Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Heptares Therapeutics Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Heptares Therapeutics Limited - Drug Profiles
    • HTL-9936
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HTL-1071
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HTL-14242
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HTL-6641
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GPR39 for Type 1 and Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize GPCR for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target GPCR for Undisclosed Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize CXCR4 for Cancer and HIV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target GPCR for CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target mGluR2 for Schizophrenia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target GPCR for Pain, Cardiovascular, Metabolic and Inflammatory Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Heptares Therapeutics Limited - Pipeline Analysis
    • Heptares Therapeutics Limited - Pipeline Products by Target
    • Heptares Therapeutics Limited - Pipeline Products by Route of Administration
    • Heptares Therapeutics Limited - Pipeline Products by Molecule Type
    • Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action
    • Heptares Therapeutics Limited - Recent Pipeline Updates
  • Heptares Therapeutics Limited - Dormant Projects
  • Heptares Therapeutics Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Heptares Therapeutics Limited, Key Information
  • Heptares Therapeutics Limited, Key Facts
  • Heptares Therapeutics Limited - Pipeline by Indication, 2016
  • Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016
  • Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016
  • Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016
  • Heptares Therapeutics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Heptares Therapeutics Limited - Phase I, 2016
  • Heptares Therapeutics Limited - Preclinical, 2016
  • Heptares Therapeutics Limited - Discovery, 2016
  • Heptares Therapeutics Limited - Pipeline by Target, 2016
  • Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016
  • Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016
  • Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action, 2016
  • Heptares Therapeutics Limited - Recent Pipeline Updates, 2016
  • Heptares Therapeutics Limited - Dormant Developmental Projects,2016

List of Figures

  • Heptares Therapeutics Limited - Pipeline by Top 10 Indication, 2016
  • Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016
  • Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016
  • Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016
  • Heptares Therapeutics Limited - Pipeline by Top 10 Target, 2016
  • Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016
  • Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016
  • Heptares Therapeutics Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top